Multiple citrulline substrates suggest PAD4 has the potential to be a therapeutic target for cancer and cancer-associated thrombotic diseases; however, the role played by PAD4 in regulating tumor progression, particularly the regulation of epithelial–mesenchymal transition (EMT), remains controversial. Here, PADI4 is linked to neoplasm.